ICOS and asthma: The present study demonstrates that BUD, an inhaled corticosteroid widely used for the management of bronchial asthma, controls asthma inflammation modulating ICOS, cell survival, Foxp3 and IL-10 expression differently in CD4+/CD25− and in CD4+/CD25+ cells in peripheral blood.